AP NEWS

OncoImmunity Receives €2.2 Million to Roll out Its Machine-Learning Platform to Enable the Development of Personalized Cancer Immunotherapies

December 17, 2018

OSLO, Norway--(BUSINESS WIRE)--Dec 17, 2018--The bioinformatics company OncoImmunity has been awarded the prestigious EU SME Instrument funding. The company’s flagship product, the  ImmuneProfiler™,  is a unique machine learning solution that has made inroads into solving the neoantigen prediction challenge. OncoImmunity enables their partners to solve the “needle in the haystack” challenge of identifying the right cocktail of neoantigens for each individual patient, and design a vaccine or cell therapy uniquely tailored to their specific tumor.

The machine learning company is based in both Oslo Norway and Cambridge Massachusetts in the USA, and this funding will advance further its capability to tailor the  ImmuneProfiler™  for specific vaccine platforms, facilitating the design of safer and more efficacious personalized cancer vaccines.

- This project matches our ambition to position OncoImmunity as the leading supplier of neoantigen identification software in the personalized cancer vaccine market, says Dr. Richard Stratford, Chief Executive Officer and Co-founder of OncoImmunity.

- The  ImmuneProfiler™  is already a powerful antigen presentation prediction tool, with demonstrated utility in predicting antigens that are presented and visible to a patient’s T cells. With these funds OncoImmunity will further advance its generic platform to learn the precise constellation of potential neoantigens that are immunogenic in different vaccine delivery systems, says Dr. Trevor Clancy, Chief Scientific Officer and Co-founder of OncoImmunity.

About OncoImmunity :

OncoImmunity is a machine-learning company offering a proprietary technology to address the key knowledge gaps in the prediction of  bone fide  immunogenic neoantigens for personalized cancer immunotherapy. OncoImmunity’s software facilitates effective patient selection for cancer immunotherapy, and identifies optimal neoantigen targets for truly personalized cancer vaccines & cell therapies in a clinically actionable time-frame.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181217005765/en/

CONTACT: Trevor Clancy Ph.D.

CSO OncoImmunity

E-mail:trevor@oncoimmunity.com

Phone: + 47 41 43 12 42

KEYWORD: UNITED STATES EUROPE NORTH AMERICA NORWAY MASSACHUSETTS

INDUSTRY KEYWORD: TECHNOLOGY DATA MANAGEMENT SOFTWARE HEALTH BIOTECHNOLOGY MEDICAL DEVICES ONCOLOGY PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: OncoImmunity

Copyright Business Wire 2018.

PUB: 12/17/2018 02:47 PM/DISC: 12/17/2018 02:47 PM

http://www.businesswire.com/news/home/20181217005765/en

AP RADIO
Update hourly